Home › Brands › Holigen
⚐ Flag an error How this page was made

Holigen

Portuguese medical cannabis cultivator with unclear current operational and ownership status.

Automated fact-check pass
5 cited sources
Published
Last reviewed
How this page was made
↯ The honest take

Holigen is a Portuguese company that held medical cannabis cultivation licenses, but its current operational status is difficult to verify. The parent company, Akanda, has faced severe financial difficulties since going public in 2022, including share-price collapse and Nasdaq deficiency notices. Any claims about Holigen's current production, ownership, or supply agreements should be verified directly with Portuguese regulators and SEC filings rather than relying on company announcements.

What we could verify

Holigen has been associated with medical cannabis cultivation under Portugal's INFARMED regulatory framework. INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde) is Portugal's medicines regulator and oversees medical cannabis cultivation licenses. Portugal's legal framework permits cultivation and export of medical cannabis under EU-GMP standards under law 33/2018 [1]. Holigen was reported to have been acquired by Australian company The Flowr Corporation in 2019 [2]. In 2021–2022, Holigen's assets were merged or transferred into Akanda Corp, which listed on Nasdaq in March 2022 [3][4]. Akanda has since disclosed significant financial distress, including Nasdaq deficiency notices and going-concern doubts in SEC filings [5]. As of 2023, Akanda announced plans to sell assets, but completion and current ownership structures require verification in current regulatory filings [5].

Why the name alone does not confirm anything

"Holigen" does not appear in public strain databases, seed banks, or as a documented consumer brand No data. The name has been used by a corporate entity in regulatory and press announcements, but this does not confirm current ownership, operational status, licensing validity, or supply relationships. Cannabis brand names and company structures change frequently, and corporate announcements (particularly merger or asset-sale announcements) do not automatically reflect completed transactions or ongoing commercial activity. Journalism covering Portuguese medical cannabis cultivation has documented gaps between announced cultivation capacity at multiple sites and documented commercial supply reaching patients or pharmacies. Anyone encountering "Holigen" cannabis for sale should treat it as an unverified claim unless independently confirmed.

How to verify if you encounter Holigen for sale

If cannabis labeled "Holigen" is offered for sale, check the following before purchase:

  1. Certificate of Analysis (CoA): Demand a current lab report from an accredited testing facility, showing cannabinoid profile, residual solvents, pesticides, and microbiology Strong evidence. A valid CoA includes the testing lab's accreditation, the test date, batch number, and contact information for the issuing lab.
  1. Breeder and batch documentation: Ask for verifiable breeder records or batch documentation showing cultivation location, harvest date, and grower licensing. Holigen's Portuguese cultivation licenses (if current) would be verifiable through INFARMED's published licensee list.
  1. Seller legitimacy: Verify that the seller is a licensed pharmacy or medical distributor in a jurisdiction where medical cannabis is legal and regulated (e.g., Germany, UK, Portugal under specific authorization) [1]. Recreational sale remains illegal in Portugal despite decriminalization of personal possession.
  1. Parent company status: Check Akanda Corp's current SEC filings (10-K, 20-F, 6-K) to confirm whether Holigen assets are still owned by Akanda, have been sold, or are in dispute [5]. Nasdaq delisting risk or asset sales affect supply chain reliability.

A legitimate medical cannabis product should include all of the above. Absence of any one of them is a red flag.

Regulatory and corporate uncertainty

Akanda Corp, Holigen's parent company, has faced significant difficulties since its March 2022 Nasdaq listing. The company's share price fell sharply within months, and it received multiple Nasdaq deficiency notices related to minimum bid price and stockholders' equity [5]. Akanda disclosed going-concern doubts in SEC filings, indicating uncertainty about the company's ability to continue operations [5]. In 2023, Akanda announced restructuring and asset sales, but whether these transactions have completed and which entity (if any) currently holds cultivation assets requires verification in current SEC filings [5]. No independent journalism has confirmed sustained, documented supply of Holigen-cultivated cannabis reaching European pharmacies at volumes consistent with announced capacity. The gap between press announcements and verifiable commercial activity is a known pattern in the European medical cannabis sector.

Similar documented brands and next steps

If you are researching medical cannabis cultivation companies or brands with transparent regulatory and commercial documentation, consider reviewing profiles of comparable companies such as Grow Pharma (Grow Group), Organigram, and Wynk, which operate under regulated frameworks in different jurisdictions. Each maintains different levels of public transparency.

If you have verifiable information about Holigen:

If you hold a current INFARMED cultivation license in Holigen's name, a batch certificate of analysis, company ownership documents, or supply agreements, flag this article with the documentation. Weedpedia welcomes breeder records, lab reports, and regulatory confirmations that help update brand profiles. Updated information should include the source's publication date and any verifiable link to public records.

Sources

  1. Government Assembleia da República. Lei n.º 33/2018, de 18 de julho - Utilização de medicamentos, preparações e substâncias à base da planta da canábis para fins medicinais.
  2. Reported Marijuana Business Daily. Flowr completes Holigen acquisition, eyes European medical cannabis market. 2019.
  3. Reported MJBizDaily. Akanda completes IPO on Nasdaq, raising $16 million. March 2022.
  4. Government U.S. Securities and Exchange Commission. Akanda Corp Form F-1 Registration Statement, filed 2021–2022.
  5. Government U.S. Securities and Exchange Commission. Akanda Corp SEC filings (10-K, 20-F, 6-K, ongoing).

How this page was made

Generation history

Oct 31, 2026
Fact-check pass — raised 6 flags
Oct 31, 2026
Revision
Jun 8, 2026
Fact-check pass — raised 3 flags
Jun 8, 2026
Initial draft

Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.